IP
33
3
AMZN
59
4
D
33
-4
CCL
41
-3
WDC
58
3
GME
65
3
VRTX
58
-2
BIIB
45
3
PPG
64
3
WHR
36
-10
UHS
62
-2
FLS
55
3
PFG
43
-3
HES
79
2
RIG
50
4
CHK
43
2
ZBH
48
-2
OKE
71
-3
PNR
72
10
LLY
56
2
IP
33
3
AMZN
59
4
D
33
-4
CCL
41
-3
WDC
58
3
GME
65
3
VRTX
58
-2
BIIB
45
3
PPG
64
3
WHR
36
-10
UHS
62
-2
FLS
55
3
PFG
43
-3
HES
79
2
RIG
50
4
CHK
43
2
ZBH
48
-2
OKE
71
-3
PNR
72
10
LLY
56
2
Financhill
Back

Perspective Therapeutics 10K Form

Buy
77

CATX
Perspective Therapeutics

Last Price:
1.66
Seasonality Move:
1.64%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.55M
Cash Flow: $-9.1M
Price / Cash Flow: 0
Annual Sales: $0.27
Price / Book: 12.33

Profitability

EPS (TTM): -0.17160
Net Income (TTM): $-46.51M
Gross Margin: $817K
Return on Equity: -50.74%
Return on Assets: -44.83%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • The Interest Expense is -0.18% of Operating Income.
  • Per Share Earnings over the last 30 years have been positive in 16 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 1.07
Quick Ratio: 0.66

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Buy
77
Perspective Therapeutics (CATX) is a Buy

Is Perspective Therapeutics a Buy or a Sell?